glp 1 agonist in ckd Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation Glucagon-like Peptide Receptor Agonists and

Back Randle, PJ (29 May 1954) 'Assay of plasma insulin activity by the rat-diaphragm method', British Medical Journal , 1, 1237-40

P-rank scores show that SGLT-2 inhibitors were ranked first in reducing HHF (100%) (Additional file 1: Table S2)

[DOI] [PMC free article] [PubMed] [Google Scholar] 155.Aviles-Olmos I, et al

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions

In addition, it is recommended that the duration of future clinical trials of GLP-1RAs for AD extend to 2 to 3 years to evaluate long-term outcomes, including changes in cognition, activities of daily living, instrumental activities of daily living, and biomarkers for tau and A